Background: Nasopharyngeal carcinoma is a squamous cell malignancy derived from the nasopharyngeal epithelial layer. This study aimed to calculate the IL-6 levels in patients with nasopharyngeal carcinoma before and after radiotherapy, in the week I and week 3 during the radiotherapy, and 2 weeks after the radiotherapy. Methods:The study was conducted in a prospective cohort on 16 people suffering from nasopharyngeal carcinoma and undergoing radiotherapy, i.e. 9 patients were in stage I of nasopharyngeal carcinoma and 7 people were in stage II of nasopharyngeal carcinoma. Each sample underwent the examination of IL-6 before the week I and week 3 during the radiotherapy, and 2 weeks after the radio¬therapy.Results: The more they received the treatment with radiotherapy the greater was the decrease of serum IL-6. The percentages of the decrease of the levels of serum IL-6 was greater in those receiving the 3-week duration of radiotherapy (24.59%) compared to those who just received 1-week duration of radiotherapy (6.44%). The decrease of serum IL-6 would continue, although radio-therapy had ended; 2 weeks after the radio-therapy, the percentage of serum IL-6 decreased to 42.43% from the level of serum IL-6 before the radio-therapy. Conclusions:The research results indicated that there happened a significant decrease of serum IL-6 (p<0.05) after the treatment with the radio-therapy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.